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Objective: The purpose of this study was to clarify the significance of bivariate
cytokeratin and DNA flow cytometry for analysis of the biologic aggressiveness of
resectable non–small cell lung cancer.
Methods: In 92 patients who underwent curative operations, the DNA ploidy status
and S-phase fractions of the cancer cell populations inside the tumors were analyzed
by a cytokeratin gating technique with paraffin-embedded specimens and were
correlated with the surgical results.
Results: Ninety tumors yielded assessable DNA histograms. DNA diploidy was
detected in 25 tumors with a mean S-phase fraction of 14.3%  4.7%, and DNA
aneuploidy was detected in 65 tumors with a mean S-phase fraction of 15.1% 
7.1%. The 5-year overall and recurrence-free survivals were 73.3% and 70.3%,
respectively. Multivariate analysis showed that only TNM staging was a prognostic
factor after surgery. There was a negative correlation between the logarithms of
S-phase fraction and the disease-free interval for 22 patients with proven recurrence
(P  .006). The tumors with high S-phase fractions recurred more rapidly than did
those with low S-phase fractions.
Conclusion: In a bivariate analysis of cytokeratin and DNA flow cytometry in
resectable non-small cell lung cancer, the S-phase fraction appeared to be correlated
with the disease-free interval. However, DNA ploidy and S-phase fraction were not
predictive of either recurrence or survival after operation. Thus DNA flow cytom-
etry may be of limited use for the analysis of the biologic aggressiveness of lung
cancer.
Primary lung cancer has recently become the most common cause ofcancer-related death in Japan, and the incidence of this malignancycontinues to rise.1 Moreover, the marked biologic aggressiveness oflung cancer causes patients to have a poor prognosis despite vigoroustreatment. The surgical removal of a lung tumor offers a chance forcure, but the overall survival after resection for patients with non–
small cell lung cancer (NSCLC) is far from satisfactory. To improve the prognosis
of lung cancer, good biomarkers that can be used to guide treatment strategy must
be identified, and an innovative multimodal approach that includes effective adju-
vant therapy needs to be developed.
DNA ploidy and proliferative activity analyzed by flow cytometry have been
established as useful indicators for the biologic aggressiveness of various neo-
plasms.2,3 Because flow cytometry is fast and quantitative, it has the potential to be
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a reliable method for investigators. The reliability of the
data measured by flow cytometry may depend strongly on
the quality of the sample, rather than on the capability of the
cytometer. In practice, the data from cancer tissue include
errors caused by stromal cells and infiltrating lymphocytes
inside the tumors, and this inaccuracy may have affected the
results in previous studies of proliferative activities.4 Re-
cently, an immunofluorescent staining step for the cytoker-
atins of cancer cells has been adopted in the preparation for
flow cytometry to detect only cancer cells and not nonepi-
thelial cells, and this has provided more accurate cancer-
specific analyses of clinical specimens.5,6
The aim of this study was to clarify the ability of biva-
riate cytokeratin and DNA flow cytometry with paraffin-
embedded specimens to predict the biologic aggressiveness
of resectable NSCLC. Accordingly, the associations of tu-
mor DNA ploidy and S-phase fraction (SPF) with the sur-
gical prognoses were assessed. Furthermore, to verify
whether tumors with a high proliferative activity grow faster
and recur earlier, the disease-free intervals (DFIs) of pa-
tients with recurrence after surgery were correlated with
their SPF values.
Patients and Methods
Patients
This study was performed on 92 patients with primary NSCLC
who underwent curative operations and received no induction
therapy between January 1, 1993, and December 31, 1996, at the
University Hospital, Kinki University School of Medicine, Osaka,
Japan. Written, informed consent was obtained from all patients.
The patients were reexamined every 3 months for the first 2 years
and at an interval of 6 months thereafter, according to the routine
follow-up scheme. The follow-up records updated to December
31, 2000, were used for this study.
Flow Cytometry
From each formalin-fixed and paraffin-embedded specimen ob-
tained from surgically resected lung carcinoma, 4-m thick slices
for hematoxylin and eosin staining and 70-m thick slices for flow
cytometry were prepared. After the 70-m sections were removed
from paraffin and rehydrated, the tumor-enriched areas were cut
off from the sections during viewing of the corresponding hema-
toxylin and eosin stained area. The samples were incubated with
0.1% collagenase (Worthington Biochemical Corporation, Lake-
wood, NJ) in phosphate-buffered saline solution, pH 7.4, with 1%
bovine serum albumin at 37°C overnight. After washing in phos-
phate-buffered saline solution, samples were digested with 0.2%
pepsin in 1N hydrochloric acid and 0.9% saline solution for 20
minutes at 37°C. The digested samples were filtered through a
nylon mesh and washed in saline solution buffered with tris(hy-
droxymethyl)aminomethane, pH 7.4, supplemented with 1% bo-
vine serum albumin (BSA-TBS). Finally, the single cells were
suspended in 100 L of BSA-TBS. The suspensions were incu-
bated with 20 L of the monoclonal anticytokeratin antibody
reagent (1:500) clone C-11 (Sigma, St Louis, Mo) or MOPC-21
(Sigma), an isotype control reagent of mouse immunoglobulin G1,
for 90 minutes at 4°C. The samples then were incubated sequen-
tially with 20 L of a fluorescein isothiocyanate-conjugated anti-
mouse immunoglobulin G antibody reagent and 5 g of 7-amino-
actinomycin D (Sigma) for 30 minutes at room temperature. After
washing, 5  106 cells were resuspended in 1 mL of BSA-TBS.
The samples were analyzed with a FACS Calibur (Becton Dick-
inson, San Jose, Calif). Fluorochromes were excited with a single
488-nm argon laser. Fluorescein isothiocyanate fluorescence was
detected through a 530  15 nm band-pass filter, and 7-amino-
actinomycin D fluorescence was detected through a 650-nm long-
pass filter. For each sample at least 30,000 events were counted.
Samples with a coefficient of variation of more than 8% were
excluded from the flow cytometric analyses, according to the
recommendation for useful S-phase determinations by Shankey
and associates.4 The acquired data were analyzed with ModFit
software (version 2.0; Verity Software House, Topsham, Maine).
Figure 1. Bivariate cytokeratin and DNA flow cytometry. A, Dot plot of DNA content (x-axis) versus cytokeratin
immunofluorescence (y-axis). Box indicates gate for cytokeratin immunoreactivity. B, DNA histogram of total cells
with SPF of 12.8%. C, DNA histogram of cytokeratin-positive cells with SPF of 14.1%.
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The SPF was calculated from a DNA histogram of the cells gated
for cytokeratin positivity (Figure 1). The SPF values were divided
into two groups: a high-SPF group, defined as having SPF greater
than the median of all assessable tumors, and a low-SPF group,
defined as having SPF less than the median.
Statistical Analysis
Where appropriate, the data were expressed as mean  SD.
Differences between two sets of data were tested with the t test, the
Mann-Whitney test, or the Kruskal-Wallis test for continuous
variables and with the 2 test for categorical variables. Correla-
tions between two variables were evaluated with the Spearman
rank correlation coefficient. The probability of cumulative cancer-
related survival was calculated by the Kaplan-Meier method. Pa-
tients who died of unrelated causes were treated as censored cases.
Differences in survival were tested with the log-rank test for
univariate analysis and with the Cox’s proportional hazard model
for multivariate analysis.
Results
The patient population consisted of 70 male and 22 female
patients, with a mean age of 63.4 years (range 27-82 years).
The lung tumors were histologically classified according to
the World Health Organization criteria as follows: adeno-
carcinoma (n  44), squamous cell carcinoma (n  35),
adenosquamous carcinoma (n  8), and large cell carci-
noma (n  5).7 The disease status was determined accord-
ing to the TNM staging system: stage IA (n  27), stage IB
(n  28), stage IIA (n  2), stage IIb (n  18), stage IIIA
(n  14), and stage IIIB (n  3) (Table 1).8 All patients
underwent a curative operation combined with mediastinal
lymphadenectomy. A lobectomy was performed in 83 pa-
tients, bilobectomy was performed in 2 patients, and pneu-
monectomy was performed in 7 patients. Among the lobec-
tomy procedures, 8 patients underwent extended resections
with removal of the involved chest wall and 1 patient had
the involved pericardium removed. The median follow-up
period was 44.7 months (range 1-83 months). Twenty-two
patients had disease recurrence, and 27 patients died. There
were 5 operative deaths, 17 cancer-related deaths, and 5
unrelated deaths.
Of all 92 tumors, 2 tumors had DNA histograms with a
coefficient of variation greater than 8.0% and were therefore
excluded. The remaining 90 tumors yielded adequate DNA
histograms, with a mean coefficient of variation of 6.3 
1.2. DNA diploidy was detected in 25 tumors and DNA
aneuploidy was detected in 65 tumors. The mean SPF of the
90 analyzable tumors was 14.94%  6.5%, and the median
TABLE 1. Pathologic factors and DNA flow cytometric measurements
Factors
DNA ploidy pattern
P
value* SPF (n  90)
P
value†
All patients
(n  92)
Diploid
(n  25)
Aneuploid
(n  65)
Histologic type .33 .32
Adenocarcinoma 44 10 32 13.6% 6.6%
Squamous cell
carcinoma
35 12 23 15.5% 5.5%
Adenosquamous
carcinoma
8 3 5 16.8% 8.6%
Large cell carcinoma 5 0 5 18.2% 8.6%
Primary tumor (T) .25 .71
pT1 33 8 24 14.9% 7.6%
pT2 41 10 30 15.4% 5.9%
pT3 15 7 8 13.9% 6.5%
pT4 3 0 3 12.7% 2.4%
Regional lymph nodes (N) .64 .14
pN0 68 17 49 14.4% 6.4%
pN1 11 3 8 13.6% 7.0%
pN2 13 5 8 18.2% 6.1%
Pathologic stage .27 .69
IA 27 6 20 13.8% 7.2%
IB 28 6 21 15.2% 5.8%
IIA 2 0 2 13.8% 8.4%
IIB 18 6 12 14.7% 6.8%
IIIA 14 7 7 16.9% 7.1%
IIIB 3 0 3 12.7% 2.4%
SPF is shown as mean  SD.
*P value for difference in DNA ploidy.
†P value for difference in SPF distribution.
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was 14.6%. The mean SPFs of the DNA diploid and aneu-
ploid tumors were 14.3%  4.7% and 15.1%  7.1%,
respectively, which were not significantly different (P 
.64). Thus DNA diploid and aneuploid tumors had equal
proliferative activities. Moreover, the DNA ploidy and SPF
were also independent of the conventional pathologic fac-
tors (histologic type, TNM classification, and pathologic
stage; Table 1).
Survival after surgery was analyzed for 87 patients (ex-
cluding the 5 operative deaths). The 5-year overall survival
and recurrence-free survivals for all 87 patients were 73.3%
and 70.3%, respectively. According to histologic type, the
5-year overall and recurrence-free survivals were 68.3% and
71.9% for the 42 patients with adenocarcinoma, 80.9% and
70.5% for the 33 with squamous cell carcinomas, 80.0% and
62.5% for the 8 with adenosquamous cell carcinomas, and
75.0% and 75.0% for the 4 with large cell carcinomas,
respectively. The histologic type did not significantly influ-
ence survival. According to the pathologic staging, the
5-year overall and recurrence-free survivals were 83.7% and
81.2% for the 52 patients with stage I disease, 71.4% and
70.2% for the 20 with stage II disease, and 39.7% and
34.3% for the 15 with stage III disease, respectively. Pa-
tients with stage I and III disease had a significant difference
in overall survival (P  .0003), as did those with stage II
and III disease (P  .03). The patients with stage I and III
disease also had a significant difference in recurrence-free
survival (P  .0006). According to DNA ploidy, the 24
patients with DNA diploid tumors had 5-year overall and
recurrence-free survivals of 88.9% and 80.8%, respectively.
The 61 patients with DNA aneuploid tumors had 5-year
overall and recurrence-free survivals of 69.3% and 67.5%,
respectively. Those with DNA diploid tumors tended to
have a better prognosis than did those with DNA aneuploid
tumors, but the differences in overall and recurrence-free
survivals were not significant (P  .15 and P  .26,
respectively). For the analysis of proliferative activity, the
prognoses of the high- and low-SPF groups (above and
below the median SPF, respectively) were compared. The
high-SPF group (n 41) had 5-year overall and recurrence-
free survivals of 77.8% and 68.7%, respectively. The low-
SPF group (n  44) had 5-year overall and recurrence-free
survivals of 73.8% and 74.0%, respectively. The high- and
low-SPF groups had statistically equivalent overall and
recurrence-free survivals (P  .82 and P  .27, respective-
ly). Multivariate analysis showed that only TNM staging
was a prognostic factor after surgery and that DNA ploidy
and proliferative activity were not significant predictors
(Table 2).
The DFIs from surgery to documented recurrence in 22
patients were correlated with the DNA flow cytometric
parameters. The 4 patients with DNA diploid tumors had a
mean DFI of 17.5  7.0 months, whereas the 18 with DNA
aneuploid tumors had a mean DFI of 17.0  11.9 months.
There was no significant difference in the DFI between
those with DNA diploid and aneuploid tumors (P  .76).
The high-SPF group (n 12) had a mean DFI of 10.8 3.6
months, whereas the low SPF group (n  10) had a mean
DFI of 24.5  12.4 months. The DFIs of the high-SPF
group were significantly shorter than those of the low-SPF
TABLE 2. Multivariate analysis of independent prognostic factors after surgical therapy according to the Cox proportional
hazards model
Variable
Overall survival Recurrence-free survival
Hazard
ratio
95% Confidence
interval P value
Hazard
ratio
95% Confidence
interval P value
Histologic type
Adenocarcinoma
(n  42)
3.2 0.7-13.5 .11 1.2 0.4-3.2 .77
Squamous cell
carcinoma (n  33)
1 1
Pathologic stage
I (n  52) 1 1
II (n  20) 1.6 0.3-8.5 .57 1.8 0.5-6.0 .30
III (n  15) 21.2 5.1-86.7 .0001 5.8 1.9-17.2 .001
DNA ploidy pattern
Diploid (n  24) 1 1
Aneuploid (n  61) 4.2 0.8-20.0 .07 2.5 0.8-7.8 .10
SPF
Low-SPF group
(n  44)
1 1
High-SPF group
(n  41)
1.5 0.3-6.2 .58 1.5 0.5-4.3 .43
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group (P  .003). There was a significant negative corre-
lation between the logarithms of SPF and DFI (p  0.006),
which indicates that the SPF was inversely proportional to
the DFI (Figure 2).
Discussion
Analyses of the cell kinetics and various markers of cell
proliferation may be reliable approaches to study the bio-
logic aggressiveness of cancer.2,3 To date, the development
of programs that use the mathematic models to calculate the
cell cycle fractions from a DNA histogram and a process for
paraffin-embedded specimens reported by Hedley and co-
workers9 has led to the widespread clinical use of DNA flow
cytometric analysis of cell proliferation. However, the
downside to this rapid evolution is variability in sample
preparation, which may cause discrepancies in reported
results. It was therefore hoped that a standard, universally
used procedure would be established.4,10
One of the technical problems in cell cycle analysis from
a DNA histogram is the presence of nontumor cells inside
tumors. When the population of nontumor cells is a signif-
icant percentage of the total, a large error in the flow
cytometric data may result. To diminish these errors, the
technique of cancer-specific flow cytometry with cytokera-
tin gating was recently established. Cytokeratins, a family
of intermediate filament proteins, are components of epithe-
lial cytoskeletons. This technique enables one to gate cancer
cells differently from nonepithelial cells and can be con-
ducted with paraffin-embedded tissue.5,6 In the strict sense,
however, this method cannot provide a cancer-specific anal-
ysis, because normal epithelial cells inside tumors have
cytokeratins and can pass through the gate operation.
The establishment of a model to simulate tumor growth
is helpful for predicting the clinical prognoses of patients
with malignant tumors. Steel reported that the actual vol-
ume doubling time (Tact) is given by the following function:
Tact    Ts/[SPF  (1  )], where Ts is the duration of
DNA synthesis,  is the correction factor, and  is the cell
loss factor.11,12 Furthermore, taking logarithms of this equa-
tion leads to the following equivalent expression: log-
(Tact)  log[  Ts/(1   )]  log(SPF). This study, which
was performed under the assumption that the DFI is equiv-
alent to Tact in this theoretical formula, demonstrated that
the SPF is inversely correlated with the DFI in NSCLC.
Therefore the significance of bivariate cytokeratin and DNA
flow cytometry is just rough estimation of the DFI without
determination of the SPF and Ts with a toxic method, such
as the tritiated thymidine labeling method or the bromode-
oxyuridine labeling method.13-15
It has been established that DNA ploidy is generally a
good indicator of a tumor’s biologic aggressiveness. Some
studies of lung cancer that incorporated DNA flow cytom-
etry found that the proliferative activity of DNA aneuploid
tumors was higher than that of DNA diploid tumors,16-18
whereas other studies found that there were no differences
in proliferative activity between DNA ploidy patterns.14,19,20
In this study the putative higher proliferative activity of
DNA aneuploid tumors could not be proved for NSCLC,
even with accurate SPF analysis with the cytokeratin gating
method. Previous studies that found DNA diploid tumors to
have low proliferative activity may have underestimated the
SPF because of the presence of normal cells inside the
tumors. To clarify whether there is any difference in the
proliferative activity between DNA diploid and aneuploid
tumors, a large-scale study will be necessary.
Whether DNA flow cytometry is useful in determining
the surgical prognosis of patients with NSCLC remains a
matter of debate.2,3,21-27 Multivariate analysis in this study
revealed that DNA ploidy and proliferative activity were not
prognostic factors. The lack of significance of DNA ploidy
with respect to both the surgical prognosis and the prolif-
erative activity suggests that there may be little difference,
if any, between DNA diploid and aneuploid NSCLC tumors
in biologic aggressiveness. Similarly, patients with high-
SPF tumors had the same prognoses as did those with
low-SPF tumors, despite the previously mentioned correla-
tion of SPF with the tumor growth rate. One possible
explanation for this is that the SPF is not directly associated
with the ability of a tumor to metastasize and therefore
would not be a reliable predictor of recurrence. Because our
statistical analysis included patients who did not have a
recurrence and were possibly cured, there might be no
Figure 2. Correlation between natural logarithms of SPF (as per-
centage) and DFI (in months) among the patients with recurrence
after surgery. These variables have significant negative correla-
tion (P  .006).
Otsuka et al General Thoracic Surgery
The Journal of Thoracic and Cardiovascular Surgery ● Volume 124, Number 2 297
G
TS
significant difference in the survivals between the high- and
low-SPF groups. The number of patients with stage II and
III disease who had high risk of recurrence was small, and
this sample-size issue could have affected other results in
this study. Because of the small patient population with
stage II disease, censored cases could largely bias the result
of prognosis, which was indeed better than universal knowl-
edge. Furthermore, with regard to future treatment strate-
gies, it appears informative that tumors with DNA aneu-
ploidy or high proliferative activity have good responses to
chemotherapy.28-30 For NSCLC, the prognoses of those with
DNA aneuploid or high SPF tumors might be improved by
the skillful use of adjuvant therapy.
In conclusion, more accurate DNA flow cytometric anal-
ysis of resectable NSCLC with the cytokeratin gating
method revealed that the SPF value was correlated inversely
with the DFI. However, DNA ploidy and SPF were not
useful for predicting either recurrence or survival after
surgery. The ability of DNA flow cytometric data to esti-
mate the biologic aggressiveness of NSCLC is limited at
best.
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